A retrospective study to assess diseases outcomes and tolerability of second-line nivolumab in a series of metastatic renal cell carcinoma patients in real life settings
Latest Information Update: 27 Oct 2020
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 27 Oct 2020 New trial record
- 31 Aug 2020 Results published in the Croatian Medical Journal